During the corresponding time, Charles River Laboratories International Inc saw a revenue deteriorated by -2.72 % year on year, sequentially revenue grew by 0.83 %. While revenue at the Charles River Laboratories International Inc 's corporate clients
Charles River Laboratories International Inc's Comment on Sales, Marketing and Customers
The company provides services to pharmaceutical and biotechnology firms, government agencies, academic institutions, commercial clients, hospitals, and universities. Its Research Model Services include Insourcing Solutions, Genetically Engineered Models and Services (GEMS), and Research Animal Diagnostic Services (RADS). Insourcing Solutions encompass managing research operations such as recruitment, training, staffing, and management within client facilities or the company's own laboratories. GEMS focuses on creating, breeding, and maintaining genetically engineered models for biomedical research, supporting clients globally. RADS offers health monitoring and analysis of research models and biologics, functioning as either a sole-source or alternative testing laboratory. The company is recognized as a reference laboratory and a leader in laboratory animal diagnostics.
News about Charles River Laboratories International inc Contracts
Charles River and Akron Bio Collaborate to Integrate CGMP Cytokines into Cell Therapy Platform WILMINGTON, Mass. In a strategic move to enhance operational capabilities and address the growing demands of the cell therapy sector, Charles River Laboratories International, Inc. (NYSE: CRL) has announced a collaboration with Akron Bio, a leading supplier of critical materials and services for advanced therapies. The partnership aims to integrate Akron s Closed System Solutions (CSS) line of liquid cytokines, manufactured under current good manufacturing practices (CGMP), into Charles River s Cell Therapy Flex Platform for process development.This integration is expected to bolster the efficiency and scalabil...
Streamlining Cell and Gene Therapy Research and Development: Charles River Launches Reference Materials for Viral VectorsWILMINGTON, Mass. - Charles River Laboratories International, Inc. (NYSE: CRL) announced today the launch of its reference materials for adeno-associated virus (AAV) and lentiviral vector (LVV) portfolio. The move aims to streamline and enhance Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice (GMP) quality. With this introduction of six AAV reference material serotypes, Charles River is setting a new gold standard for reference materials in the field.Cell and Gene Therapy has emerged as a promising frontier in modern medicine, offering target...
In a recent announcement, Charles River Laboratories International, Inc. has entered into a collaboration agreement with Pluristyx Inc., a renowned provider of tools, technologies, and services for cell therapy development. This collaboration expands Charles River s access to a wide range of highly characterized and unique stem cell lines, including embryonic stem cells (ES) and induced pluripotent stem cells (iPSCs). This article will outline the key facts and developments related to this partnership, as well as highlight a significant manufacturing milestone achieved by Charles River in its cell therapy collaboration with Vertex Pharmaceuticals.Expanding Stem Cell Portfolio:Charles River Laboratories Inter...
In a significant step forward for cell therapy manufacturing, Charles River Laboratories International, Inc. (NYSE: CRL) and Vertex Pharmaceuticals have announced an important milestone in their strategic collaboration. This breakthrough revolves around the production of CASGEVY (exagamglogene autotemcel exa-cel), an innovative treatment approved in select countries for eligible patients. The achievement comes as Charles River s Memphis center of excellence successfully cleared consecutive audits from both the U.S. Food and Drug Administration (FDA) and the Health Products Regulatory Authority (HPRA). These audits validate the facility s adherence to stringent quality control measures and regul...
Charles River Laboratories International Inc’s Comment on Sales, Marketing and Customers
The company provides services to pharmaceutical and biotechnology firms, government agencies, academic institutions, commercial clients, hospitals, and universities. Its Research Model Services include Insourcing Solutions, Genetically Engineered Models and Services (GEMS), and Research Animal Diagnostic Services (RADS). Insourcing Solutions encompass managing research operations such as recruitment, training, staffing, and management within client facilities or the company's own laboratories. GEMS focuses on creating, breeding, and maintaining genetically engineered models for biomedical research, supporting clients globally. RADS offers health monitoring and analysis of research models and biologics, functioning as either a sole-source or alternative testing laboratory. The company is recognized as a reference laboratory and a leader in laboratory animal diagnostics.
Sources:
Charles River Laboratories International inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Charles River Laboratories International inc’s corporate clients.
For your research, we’ve provided 9 tables on Charles River Laboratories International inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
159.99 %